Skip to main content

Table 1 Baseline characteristics

From: High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis – a randomized controlled trial

  Vitamin D group (N = 35) Placebo group (N = 33)
Females N (%) 24 (69) 24 (73)
Age (years) Mean (range) 40 (21–50) 41 (26–50)
Body mass index Mean (range) 25.9 (21.0–40.7) 26.4 (18.4–39.9)
Ongoing smoking N (%) 15 (43) 14 (42)
EDSS Median (range) 2.5 (0–4.5) 2.0 (0–4.5)
Annualised relapse rate Mean (range) 0.11 (0–0.54) 0.15 (0–1.10)
Immunomodulatory treatment N (%) 17 (49)a 17 (52)b
Serum 25(OH)D (nmol/L) Mean (SD) 55.6 (29.0) 57.3 (21.8)
Hip BMD (mg/cm2) Mean (SD) 1018.8 (98.8) 968.9 (119.9)
Spine BMD (mg/cm2) Mean (SD) 1205.2 (117.7) 1165.7 (135.6)
Distal radius BMD (mg/cm2) Mean (SD) 484.8 (67.1) 472.8 (80.6)
  1. a16 patients on IFN-β and one on glatiramer acetate
  2. b15 patients on IFN-β, one on glatiramer acetate and one on natalizumab